Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.

Journal of cellular physiology - 1 Nov 2020

Van Der Steen Nele, Keller Kaylee, Dekker Henk, Porcelli Letizia, Honeywell Richard J, Van Meerloo Johan, Musters René J P, Kathmann Ietje, Frampton Adam E, Liu Daniel S K, Ruijtenbeek Rob, Rolfo Christian, Pauwels Patrick, Giovannetti Elisa, Peters Godefridus J

Abstract excerpt

In non-small cell lung cancer, sensitizing mutations in epidermal growth factor receptor (EGFR) or cMET amplification serve as good biomarkers for targeted therapies against EGFR or cMET, respectively. Here we aimed to determine how this different genetic background would affect the interaction between the EGFR-inhibitor erlotinib and the cMET-inhibitor crizotinib. To unravel the mechanism of synergy we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Lysosomes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 31960422
DOI: 10.1002/jcp.29463
PMCID: PMC7540474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.PMID 31960422Read ↗

Epidrug Screening Identifies Type I PRMT Inhibitors as Modulators of Lysosomal Exocytosis and Drug Sensitivity in CancersSemantic proximity Read ↗

Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.Semantic proximity Read ↗

Lysosomal trapping of palbociclib and its functional implicationsSemantic proximity Read ↗

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.Semantic proximity Read ↗

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.Semantic proximity Read ↗

Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.Semantic proximity Read ↗

Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.Semantic proximity Read ↗

Folate transporter dynamics and therapy with classic and tumor-targeted antifolatesSemantic proximity Read ↗

Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).Semantic proximity Read ↗

Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.Semantic proximity Read ↗

Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid TumorsSemantic proximity Read ↗

Effective Tyrosine Kinase Inhibitors result in the intracellular accumulation of EGFR and allows response prediction in patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.